日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Enhanced MAPK signaling drives ETS1-mediated induction of miR-29b leading to downregulation of TET1 and changes in epigenetic modifications in a subset of lung SCC

增强的 MAPK 信号通路驱动 ETS1 介导的 miR-29b 诱导,导致 TET1 下调和部分肺鳞状细胞癌中表观遗传修饰的改变。

Taylor, M A; Wappett, M; Delpuech, O; Brown, H; Chresta, C M

Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition

结直肠癌的内在亚型可预测化疗获益、错配修复缺陷和上皮间质转化。

Roepman, Paul; Schlicker, Andreas; Tabernero, Josep; Majewski, Ian; Tian, Sun; Moreno, Victor; Snel, Mireille H; Chresta, Christine M; Rosenberg, Robert; Nitsche, Ulrich; Macarulla, Teresa; Capella, Gabriel; Salazar, Ramon; Orphanides, George; Wessels, Lodewyk F A; Bernards, Rene; Simon, Iris M

Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055)

MEK(selumetinib)和 mTOR 激酶抑制剂(AZD8055)联合使用可增强细胞凋亡和肿瘤生长抑制

Sarah V Holt, Armelle Logie, Barry R Davies, Denis Alferez, Sarah Runswick, Sarah Fenton, Christine M Chresta, Yi Gu, Jingchuan Zhang, Yi-Long Wu, Robert W Wilkinson, Sylvie M Guichard, Paul D Smith

Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background

AKT 抑制剂 AZD5363 的临床前药理学:药效学、抗肿瘤活性以及单一疗法活性与遗传背景的相关性

Barry R Davies, Hannah Greenwood, Phillippa Dudley, Claire Crafter, De-Hua Yu, Jingchuan Zhang, Jing Li, Beirong Gao, Qunsheng Ji, Juliana Maynard, Sally-Ann Ricketts, Darren Cross, Sabina Cosulich, Christine C Chresta, Ken Page, James Yates, Clare Lane, Rebecca Watson, Richard Luke, Donald Ogilvie,

Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines

原发性结直肠肿瘤的亚型与结直肠细胞系对靶向治疗的反应相关

Schlicker, Andreas; Beran, Garry; Chresta, Christine M; McWalter, Gael; Pritchard, Alison; Weston, Susie; Runswick, Sarah; Davenport, Sara; Heathcote, Kerry; Castro, Denis Alferez; Orphanides, George; French, Tim; Wessels, Lodewyk F A

AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity

AZD8055 是一种强效、选择性、口服生物利用度高的 ATP 竞争性哺乳动物雷帕霉素激酶抑制剂,具有体外和体内抗肿瘤活性

Christine M Chresta, Barry R Davies, Ian Hickson, Tom Harding, Sabina Cosulich, Susan E Critchlow, John P Vincent, Rebecca Ellston, Darren Jones, Patrizia Sini, Dominic James, Zoe Howard, Phillippa Dudley, Gareth Hughes, Lisa Smith, Sharon Maguire, Marc Hummersone, Karine Malagu, Keith Menear, Richa

Apoptosis induction by MEK inhibition in human lung cancer cells is mediated by Bim

MEK抑制剂诱导人肺癌细胞凋亡是通过Bim介导的。

Meng, Jieru; Fang, Bingliang; Liao, Yong; Chresta, Christine M; Smith, Paul D; Roth, Jack A

High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886)

AKT活性水平高与对MEK抑制剂AZD6244(ARRY-142886)的耐药性相关

Meng, Jieru; Peng, Henry; Dai, Bingbing; Guo, Wei; Wang, Li; Ji, Lin; Minna, John D; Chresta, Christine M; Smith, Paul D; Fang, Bingliang; Roth, Jack A

Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)

Ku-0063794 是哺乳动物雷帕霉素靶蛋白 (mTOR) 的特异性抑制剂

Juan M García-Martínez, Jennifer Moran, Rosemary G Clarke, Alex Gray, Sabina C Cosulich, Christine M Chresta, Dario R Alessi